Where Fiber’s Byproducts Land in Your Gut Changes Which Appetite Hormone Fires

If you have been researching gut health because of bloating, blood sugar swings, or an appetite that never quite switches off, you have met the advice to eat more fiber so your gut bacteria make more short-chain fatty acids. A new trial complicates that advice usefully. Researchers gave the same dose of those fatty acids to the same people twice, changing only where in the intestine it was released, and got two different hormonal responses. Fiber's payoff may depend less on how much you eat than on where the fermentation products land.

Key Takeaways

• A randomized crossover trial in 28 healthy adults delivered an identical dose of short-chain fatty acids (SCFA, the compounds gut bacteria make when they ferment fiber) to either the small intestine or the colon, using capsules with different coatings.
• Colonic delivery released more PYY, an appetite-suppressing gut hormone, while small intestinal delivery released more GLP-1 and put far more SCFA into the bloodstream. The GLP-1 result was the opposite of what the researchers predicted.
• Both delivery sites lowered self-reported appetite compared with placebo, and neither one moved blood glucose.
• This was a single-dose mechanism experiment in young, healthy, normal-weight volunteers. It does not show weight loss, and it does not show that anything lasts beyond eight hours.

SCFA Delivery Site Decides Whether GLP-1 or PYY Rises

The place where short-chain fatty acids reach the gut wall determines which appetite hormone the body releases, according to a randomized crossover trial from Riet Rosseel, Kristin Verbeke and colleagues at KU Leuven, published in The American Journal of Clinical Nutrition. Delivering SCFA to the colon produced a greater release of PYY (peptide YY, a hormone released by gut cells that dampens hunger), with an estimated difference of 111.46 pg/ml.h in incremental area under the curve, a measure of total hormone released over the whole session (adjusted p = 0.04).

The surprise ran the other way. The team expected the colon to win on both hormones, because the gut's hormone-secreting L-cells get denser toward the far end of the intestine. Instead, small intestinal delivery produced more GLP-1 (glucagon-like peptide-1, the hormone that the current class of GLP-1 drugs imitates), an estimated difference of 16.00 pM.h (adjusted p = 0.03). The authors point to work suggesting GLP-1 content is roughly 3 to 5 times higher in the human jejunum and ileum, the middle and lower small intestine, than in the colon and rectum, which would explain the flip.

Why Appetite Hormone Timing Matters for Metabolic Health

Anyone tracking GLP-1 has a stake in this, because it reframes fiber as a delivery problem rather than a dosage problem. GLP-1 and PYY are the body's own satiety signals; PYY(3-36) was shown decades ago to physiologically inhibit food intake in humans, and SCFA have long been proposed as a natural lever on both, as summarized in a review of short-chain fatty acids in control of body weight and insulin sensitivity. What this trial adds is that the two hormones do not answer to the same address.

That matters for people managing obesity or type 2 diabetes, because a fiber or formulation designed to hit the small intestine would produce a different physiological result than one engineered to survive to the colon. It also matters for people with irritable bowel syndrome or inflammatory bowel disease, for an uncomfortable reason: this trial deliberately excluded them, so none of it has been tested in the group most likely to be reading about it.

Coated Capsules Let Researchers Aim a Fixed Dose at Two Gut Regions

The methodological move that makes this trial credible is that it removed the microbiome from the equation entirely. Rather than feeding people fiber and hoping their bacteria produced a comparable amount of SCFA, the team put a fixed 230 mmol dose of sodium acetate, propionate and butyrate in a 6:2:2 ratio into size 00 gelatin capsules, an amount equivalent to what fermenting 20 g of arabinoxylan oligosaccharides would yield. Uncoated capsules dissolved in the small intestine. For colonic delivery, the same capsules were coated with a pH-dependent polymer that only dissolves above pH 7.0. Placebo capsules held microcrystalline cellulose and carried the same coating.

Each of the 28 participants, 11 men and 17 women averaging 23 years old with an average BMI of 22, received all three conditions on separate visits in randomized order, so every person served as their own control. Participants were blinded; the researcher running the visits could not be, because the colon-delivery coating was visually distinguishable. For three days beforehand, volunteers avoided alcohol and ate under 10 g of fiber a day. On the day, they ate a fiber-free breakfast of omelet and white bread, swallowed their capsules, and gave blood every 30 minutes for 8 hours. The trial was preregistered on ClinicalTrials.gov as NCT06686888.

Blood SCFA Climbed Sharply While Glucose Stayed Flat

Small intestinal delivery put dramatically more SCFA into general circulation, exactly as predicted, because small intestinal cells do not consume SCFA as fuel the way colonic cells do. Compared with colonic delivery, it produced higher circulating acetate (360.33 uM.h), propionate (18.00 uM.h) and butyrate (7.21 uM.h), all with adjusted p values below 0.001. The small intestine is the better route for getting these molecules to the rest of the body; the colon is the better route for one specific local hormone signal.

Neither site shifted glucose or c-peptide, a marker of insulin secretion. That is a meaningful null: a GLP-1 bump big enough to register did not translate into measurable changes in blood sugar handling in healthy people over eight hours. The receptor machinery behind these signals was worked out in studies showing that SCFA stimulate GLP-1 secretion via the receptor FFAR2, with the broader picture in a review of short-chain fatty acids in microbiota-gut-brain communication.

What This Does and Does Not Justify Doing About Your Fiber

Nothing here justifies buying an SCFA supplement, and the trial does not establish that any fiber product changes appetite in daily life. What it does support is a more precise way of thinking about fiber: two products with identical gram counts on the label are not necessarily doing identical things to your hormones. That is worth raising with a doctor or dietitian if you are already working on appetite or glycemic control, and an unreasonable basis for self-prescribing anything.

Both routes did reduce self-reported appetite compared with placebo, on different clocks. Small intestinal effects showed up between 2 and 4 hours and cut hunger and expected food intake while raising fullness and satiation. Colonic effects arrived later, most evident at 8 hours, and raised fullness and satiation and lowered expected food intake, without significantly changing hunger. Worth knowing before anyone romanticizes colonic delivery: it also produced moderate loose stools, bowel urgency and mild diarrhea, while the small intestinal route did not.

Healthy Young Volunteers and Subjective Ratings Cap the Conclusions

The single largest limitation is the population. Every participant was healthy and normal-weight, with an average age of 23, so generalizing to people with obesity or diabetes, the exact groups a satiety intervention would target, is unsupported. Appetite was captured only through subjective ratings with no measurement of what people actually ate afterward, and the team measured total rather than active GLP-1 and PYY, which limits physiological interpretation. The fecal microbiome was not characterized, so the microbial contribution is unknown.

What Comes Next for Targeted SCFA Delivery

The obvious next step is chronic dosing in people who actually have metabolic disease, and there is precedent: an earlier trial on targeted delivery of propionate to the human colon tracked appetite regulation, body weight maintenance and adiposity in overweight adults. Pairing that kind of longer horizon with this trial's site comparison would answer the question this one cannot. The work was funded by the EU Horizon Europe HealthFerm project, with senior author Kristin Verbeke disclosing consultancy fees paid to her institution by Fresenius Kabi; the underlying data are posted publicly on Zenodo.

Common Questions

Does this mean fiber supplements can act like GLP-1 drugs? No. This trial measured the body's own GLP-1 release over eight hours after a single capsule dose, and the increase did not change blood glucose. GLP-1 medications work at sustained pharmacological levels that this study neither reached nor tested.

Is the small intestine or the colon the better target? It depends on the goal, which is the point of the trial. The colon produced more PYY; the small intestine produced more GLP-1, far more circulating SCFA, and a broader reduction in reported appetite, but only colonic delivery caused loose stools and urgency.

Can I control where my fiber ferments by choosing certain foods? Not with any precision, and this study does not test food at all. It used pH-coated capsules of purified fatty acid salts specifically to bypass the variability of eating fiber and letting bacteria do the work.

Does this apply to people with IBS or IBD? Not yet. Chronic gastrointestinal disorders including IBS, IBD and celiac disease were exclusion criteria, so the findings come only from people with healthy digestive tracts.

References

Riet Rosseel, Greet Vandermeulen, Tessa Dehau, Kristin Verbeke (2026). Small intestinal versus colonic short-chain fatty acid delivery drives distinct systemic concentrations and endocrine responses in humans: a randomized, crossover trial. The American Journal of Clinical Nutrition. https://doi.org/10.1016/j.ajcnut.2026.101470